桑格测序
PSEN1型
先证者
错义突变
阿尔茨海默病
生物标志物
外显子组测序
生物
外显子
病理
突变
神经退行性变
遗传学
医学
淀粉样前体蛋白
基因
疾病
作者
Mingrong Xia,Chenhao Gao,Huayuan Wang,Junkui Shang,Ruijie Liu,Yang You,Weizhou Zang,Jiewen Zhang
标识
DOI:10.2174/1567205019666220718151357
摘要
Background/Objective: AD-associated PSEN1 mutations exhibit high clinical heterogeneity. The discovery of these mutations and the analysis of their associations with cases such as EOAD should be critical to understand the pathogenesis of AD. Methods: We performed clinical analysis, neuroimaging, target region capture and high-throughput sequencing, and Sanger sequencing in a family of 3 generations. The underlying Alzheimer’s pathology was evaluated by using biomarker evidence obtained from cerebrospinal fluid (CSF) amyloid testing and 18F-florbetapir (AV-45) PET imaging. Results: Target region capture sequencing revealed a novel heterozygous C to T missense point mutation at the base position 284 (c.850 C>T,) located in exon 8 of the PSEN1 gene, resulting in a Proline-to-Serine substitution (P284S) at codon position 850. The mutation was also identified by Sanger sequencing in 2 family members including proband and her daughter and was absent in the other 4 unaffected family members and 50 control subjects. Cerebrospinal fluid (CSF) amyloid test exhibited biomarker evidence of underlying Alzheimer’s pathology. 18F-florbetapir (AV-45) PET imaging indicated extensive cerebral cortex and cerebellar Aβ deposition. Conclusions: We discovered a novel PSEN1 pathogenic mutation P284S, which was observed for the first time in a Chinese family with early-onset AD.
科研通智能强力驱动
Strongly Powered by AbleSci AI